Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis September 26, 2023https://www.businesswire.com/news/home/20230926244002/en/Arcturus-Therapeutics-and-Cystic-Fibrosis-Foundation-Extend-Agreement-to-Advance-ARCT-032-an-Investigational-Messenger-RNA-mRNA-Therapeutic-to-Treat-Cystic-Fibrosis
Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects April 7, 2023https://classic.clinicaltrials.gov/ct2/show/NCT05712538
